ClinicalTrials.gg
Not yet recruitingNCT07949591Updated Nov 19, 2026

Foxtail Millet (Setaria Italica (L.) P. Beauv.)-Based Diet on Postprandial Glycemic Control in Adults With Obesity and Type 2 Diabetes

An interventional study of Placebo and experimenmtal in BMI, Fasting Blood Glucose and HbA1c, sponsored by University of Lahore. Not yet recruiting at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Lahore · Not applicable, Interventional, and Health services research

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan — 28 open to participants now, 35 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Pakistan.

Planned enrollment
41st of 89
102 · median 99
Started
2026
with 15 others
No phase
59 of 98
19 open now
Primary completion
2027-04
later than 27 of 34 live
Registered
98th of 98
by date

Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, this one is the 41st largest by planned enrollment of the 89 interventional ones that give a count, is one of 16 that started in 2026, is one of 59 with no phase, reaches primary completion later than 27 of the 34 other live ones, and was the 98th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, or all of them as a file.
02

Study summary

This 10-week randomized controlled trial evaluated the nutritional quality and dose-specific effects of foxtail millet muffins (50 and 100 g/day) alongside a low-glycemic index diet among 102 obese adults with T2DM. The study will assess changes in glycemic control, lipid profile, liver function, and anthropometric parameters to investigate the potential of foxtail millet as a functional dietary intervention for diabetes management.

Read the detailed description

This 10-week randomized controlled trial investigated the nutritional quality and potential health benefits of foxtail millet (Setaria italica) muffins among 102 obese adults with type 2 diabetes mellitus (T2DM). Participants were randomly allocated into three groups: placebo (wheat muffin, T₀), low-dose foxtail millet muffin (50 g/day, T₁), and high-dose foxtail millet muffin (100 g/day, T₂), with all groups following a standardized low-glycemic index diet. The nutritional composition, including proximate constituents and mineral content, and sensory acceptability of the muffins were evaluated using standard AOAC procedures and a 9-point hedonic scale. Anthropometric measurements, including body weight, BMI, and other relevant parameters, were assessed alongside fasting blood glucose (FBG), glycated hemoglobin (HbA1c), lipid profile, and liver function biomarkers at baseline and after the intervention. The study aimed to determine whether daily consumption of foxtail millet-based muffins could provide a nutritionally valuable dietary option and support improvements in glycemic regulation, metabolic health, and anthropometric status among obese adults with T2DM.

03

Conditions studied

  • BMI
  • Fasting Blood Glucose
  • HbA1c
  • Lipid Profile
  • Liver Enzymes

Keywords

  • Type 2 diabetes mellitus
  • Glycemic control
  • Dietary intervention
  • Functional food
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People between 30 to 60 years old.
  • (BMI) ≥30.0 kg/m².
  • Fasting blood glucose levels ≥ 7.0 mmol/L (126 mg/dL).
  • Individuals having ≥ 6.5%.
  • Elevated Lipid Profile: TC > 200 mg/dL, TG > 150 mg/dL, LDL-C > 100 mg/dL, HDL-C \< 40 mg/dL (men) / \< 50 mg/dL (women).
  • Elevated Liver Function Tests: > 56 U/L, AST > 40 U/L, ALP > 147 U/L, Total > 1.2 mg/dL, Albumin \< 3.5 g/dL.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have a known allergy or have experienced any adverse reaction to foxtail millet or any of the ingredients used in the muffins will not be included in the study.
  • Patients who are taking medications known to significantly alter glucose metabolism or gastrointestinal absorption.
  • Individuals who have recently had gastric surgery or who have surgery planned during the research period.
  • Presence of other severe chronic diseases (e.g., severe renal, hepatic, or cardiovascular disease, active cancer).
  • Nursing or pregnant females.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
102 participants (estimated)

Study arms

  • Placebo comparator
    PLACEBO T0

    T₀; wheat muffin

    Dietary Supplement: Placebo

  • Experimental
    Intervention Group (T₁)

    low-dose foxtail millet muffin (T₁; 50 g/day)

    Dietary Supplement: experimenmtal

  • Experimental
    Intervention Group (T₂)

    high-dose foxtail millet muffin (T₁; 100 g/day)

    Dietary Supplement: high-dose foxtail millet muffin

Interventions

  • Dietary supplementPlacebo

    wheat muffin

  • Dietary supplementexperimenmtal

    low-dose foxtail millet muffin (T₁; 50 g/day)

  • Dietary supplementhigh-dose foxtail millet muffin

    high-dose foxtail millet muffin (T₂; 100 g/day)

06

What researchers measure

Primary outcomes

  1. bmi

    Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m²) and expressed in kg/m².

    Time frame: 10 weeks

  2. HBA1c

    Glycated hemoglobin (HbA1c) was measured to assess average blood glucose levels over the preceding 2-3 months and expressed as a percentage (%).

    Time frame: 10 weeks

Secondary outcomes

  1. LIPID PROFILE

    Lipid profile, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), was assessed and expressed in mg/dL.

    Time frame: 10 WEEKS

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Of 2,072 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 4 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Dec 5, 2026
Primary completionEst.
Apr 10, 2027
CompletionEst.
Apr 25, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949591
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 5, 2026 (estimated)
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 25, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

SANA NOREEN, PhD
Contact
SANA.NOREEN@DNSC.UOL.EDU.PK
03018661160

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion